Agreed. PF directly replied to me that patient 1 in cohort 4 had been dosed. Not what I would call a good communication strategy, but I digress, the point is that they would not have moved to cohort 4 without some type of positive data. The ASX continuous disclosure policy is at direct odds with Nasdaq listing and we will likely move everything to the US including dropping the ASX listing.
- Forums
- ASX - By Stock
- BLT
- BLT.AX says CEO and Managing Director Dr Peter French Resigned
BLT.AX says CEO and Managing Director Dr Peter French Resigned, page-38
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)